Pembrolizumab
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13872 publications
Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy.
Journal: ESMO gastrointestinal oncology
Published: October 30, 2026
Cost-effectiveness of neoadjuvant/adjuvant pembrolizumab versus standard of care for locally advanced head and Neck squamous cell carcinoma in China and the United States.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: October 30, 2026
Neoadjuvant Therapy in Mohs Surgery: A Scoping Review of the Literature.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: October 30, 2026
Time-dependent indirect comparison of enfortumab vedotin plus pembrolizumab and disitamab vedotin plus toripalimab in advanced urothelial carcinoma.
Journal: Journal of chemotherapy (Florence, Italy)
Published: October 29, 2026
KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 28, 2026
Isolated Immune Checkpoint Inhibitor-related Esophagitis.
Journal: Internal medicine (Tokyo, Japan)
Published: October 28, 2026
An International Study of Pembrolizumab for Drug-Resistant Gestational Trophoblastic Neoplasia.
Journal: NEJM evidence
Published: October 27, 2026
Unmasking Weakness: A Case of Pembrolizumab-induced Myasthenia Gravis With Concurrent Myositis.
Journal: Rhode Island medical journal (2013)
Published: October 27, 2026
First mRNA Cancer Vaccine Succeeds in Phase III Trial.
Journal: Cancer discovery
Published: October 26, 2026
Advances in the management of renal cell carcinoma.
Journal: BMJ (Clinical research ed.)
Published: October 26, 2026
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.
Journal: The New England journal of medicine
Published: October 26, 2026
Last Updated: 11/08/2026